InvestorsHub Logo
Followers 51
Posts 9143
Boards Moderated 1
Alias Born 10/25/2007

Re: None

Monday, 10/31/2022 12:45:33 AM

Monday, October 31, 2022 12:45:33 AM

Post# of 13522
On Tuesday, Morgan Stanley analyst Matthew Harrison provided an encouraging view of Moderna's upcoming analysis of a phase 2 study for its personalized cancer vaccine as an adjuvant treatment for patients with high-risk melanoma. Harrison believes Merck's recent decision to exercise its option to jointly develop and commercialize the drug suggests the results will be positive.

RELAX$$$$$$$
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent MRNA News